Stockscreener 앱 받기
779.67
0.35%
-2.71
시간 외 거래:
780.00
0.33
+0.04%
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Regeneron: A Long-Term Investment in Biotech - Intellectia AI
Regeneron Stock: Here’s Why Four Expected FDA Approvals Could Push its 36% Rally Even Higher - TIKR.com
BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850, Maintains Outperform Rating - marketscreener.com
Regeneron Pharmaceuticals, Inc. $REGN is Persistent Asset Partners Ltd's 5th Largest Position - MarketBeat
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock? - Barchart.com
China Universal Asset Management Co. Ltd. Has $12.01 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Compass Wealth Management LLC Invests $2.04 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Diabetic Macular Edema Market to Reach US$ 7.44 Billion by 2033 - openPR.com
Regeneron (REGN) Awaits FDA Decision on FOP Treatment - GuruFocus
CEO Change: Can Regeneron Pharmaceuticals Inc grow without external funding2025 Big Picture & Weekly Momentum Stock Picks - baoquankhu1.vn
Here's What Analysts Are Saying About Regeneron Pharmaceuticals (REGN) - Finviz
Here’s What Analysts Are Saying About Regeneron Pharmaceuticals (REGN) - Insider Monkey
Regeneron Pharmaceuticals Says its FOP Drug Candidate Garetosmab's BLA Gets US FDA Priority Review - marketscreener.com
Regeneron Pharmaceuticals Inc. Lowers Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Regeneron (REGN) Gains Priority Review for Garetosmab - GuruFocus
Regeneron Gets Speedy FDA Review of Garetosmab in FOP - marketscreener.com
FDA grants priority review for Regeneron’s FOP treatment - Investing.com
Regeneron wins FDA review for rare disease therapy (REGN) - Seeking Alpha
Garetosmab biologics license application accepted for FDA priority review - marketscreener.com
FDA eyes first FOP treatment as garetosmab gets Priority Review - Stock Titan
PNC Financial Services Group Inc. Has $9.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
HighTower Advisors LLC Buys 1,944 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Ex-Dividend Reminder: ONE Gas, AstraZeneca and Regeneron Pharmaceuticals - Nasdaq
Merit Financial Group LLC Buys 1,397 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Skandinaviska Enskilda Banken AB publ Lowers Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Fifth Third Bancorp Raises Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Vanguard Group Inc. Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Shell Asset Management Co. Has $276,000 Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Pallas Capital Advisors LLC Takes $1.32 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test - MedCity News
Eylea threatened Inlyta Ocular’s phase III win with Axpaxli? - BioWorld MedTech
NEOS Investment Management LLC Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
GSA Capital Partners LLP Purchases 1,358 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regeneron (REGN) Downgraded at RBC Capital, Price Target Cut Sharply - MSN
Price Over Earnings Overview: Regeneron PharmaceuticalsRegeneron Pharmaceuticals (NASDAQ:REGN) - Benzinga
Assetmark Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why is Regeneron Pharmaceuticals Inc. stock going downTrade Exit Report & AI Optimized Trade Strategies - mfd.ru
Aberdeen Group plc Sells 52,247 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded by Wall Street Zen to Hold - MarketBeat
Market Review: What are the future prospects of Regeneron Pharmaceuticals IncMarket Volume Report & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Caprock Group LLC Takes $1.47 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Is Regeneron Pharmaceuticals Inc. attractive at current valuationJuly 2025 Intraday Action & Expert Curated Trade Setup Alerts - mfd.ru
Is Regeneron Pharmaceuticals Inc. (RGO) stock in buy zone after pullback2025 Analyst Calls & High Accuracy Investment Signals - mfd.ru
Varma Mutual Pension Insurance Co Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Wealthfront Advisers LLC - MarketBeat
LSV Asset Management Takes $31.26 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cibc World Market Inc. Has $8.85 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story - simplywall.st
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Regeneron Allergy Antibodies And Dupixent Data Reframe Growth Prospects - Yahoo Finance
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? - bitget.com
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating - marketscreener.com
Krilogy Financial LLC Invests $1.18 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illinois Municipal Retirement Fund Buys 2,599 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron, Samsung Bioepis Settle Eylea Biosimilar Patent Case - Bloomberg Law News
10 Best Medical Research Stocks to Buy According to Hedge Funds - Insider Monkey
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial - TipRanks
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? - TradingView
Rhumbline Advisers Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leuthold Group LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Prospera Financial Services Inc Has $4.93 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • Pfizer - openPR.com
0.34%
1.63%
자본화:
|
볼륨(24시간):